A medicinal-chemistry dossier on asundexian (SUNHARBO) — the first approved Factor XIa inhibitor: mechanism, the originator CuAAC/Suzuki route and its chiral-pool patent-avoiding alternative, key intermediates, and the OCEANIC-STROKE data.
A medicinal-chemistry dossier on giredestrant (WILSERDLY) — the first oral SERD approved with everolimus for ER+/HER2−, ESR1-mutated advanced breast cancer: mechanism, the crystallization-driven Pictet–Spengler manufacturing route, key intermediates, and the evERA data.
Compiled: 2026-10-22 · Trigger event: FDA approval, 2026-09-25 Innovator: Mirum Pharmaceuticals, Inc. (Foster City, CA) – NDA holder and US commercial lead. ‘Licensed from: Incyte Corporation, Wilmington, DE’ and ‘ATEBRIOZ is a trademark of Incyte’ per label back page. Incyte developed the molecule…
Compiled: 2026-10-22 · Trigger event: FDA approval, 2026-09-25 Innovator: AbbVie Inc., 1 N. Waukegan Road, North Chicago, IL 60064 (Marketed by AbbVie Inc.; JUVMO is a trademark of Cerevel Therapeutics, LLC, an AbbVie company). Chain of origin: DISCOVERED AT PFIZER (Brodney, Davoren, Gray…
Compiled: 2026-10-22 · Trigger event: FDA approval, 2026-09-04 Innovator: AstraZeneca Pharmaceuticals LP (sponsor of record: ASTRAZENECA). Camizestrant (AZD9833) was discovered in-house at AstraZeneca (Scott et al., J. Med. Chem. 2020) – a fully internal asset, no in-licensing. Status:…
Mechanism: Lirafugratinib (RLY-4008) is a highly selective, IRREVERSIBLE (covalent) small-molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2). A methacrylamide (2-methylprop-2-enamide) Michael-acceptor warhead covalently engages Cys491 at the tip of the FGFR2 phosphate-binding (P)-loop (homologous Cys488 in FGFR1). Selectivity…
Mechanism: Iberdomide is a potent, orally available cereblon (CRBN) E3 ligase modulator (CELMoD). It binds CRBN — the substrate receptor of the CRL4^CRBN E3 ubiquitin ligase — and reshapes the substrate-recruitment surface to drive ubiquitination and proteasomal degradation of…
Mechanism: Brepocitinib is an oral, Type I (ATP-competitive) inhibitor that reversibly binds the catalytic JH1 kinase domain of BOTH tyrosine kinase 2 (TYK2; ChEMBL CHEMBL3553) and Janus kinase 1 (JAK1; CHEMBL2835), with relative JAK2/JAK3 sparing (enzymatic IC50 ~TYK2 23…
Mechanism: Daraxonrasib (RMC-6236) is an oral, noncovalent, beyond-Rule-of-5 macrocyclic ‘tri-complex’ (molecular-glue) inhibitor of RAS. It first binds the intracellular chaperone cyclophilin A (CypA); the drug–CypA binary complex then presents a neomorphic composite surface that engages the active, GTP-bound (‘ON’)…
Compiled: 2026-08-14 · Trigger event: FDA approval, 2025-03-25 Innovator: GlaxoSmithKline LLC (US NDA holder; composition-of-matter patents held by Glaxo Group Limited). Developed with US government biodefense co-funding (BARDA OTA HHSO100201300011C; DoD/DTRA HDTRA1-07-9-0002). Status: Approved NME Mechanism: Gepotidacin is a first-in-class, bactericidal TRIAZAACENAPHTHYLENE antibacterial that inhibits bacterial…